标题/作者	年份
SARS-CoV-2: structure, biology, and structure-based therapeutics development MY Wang, R Zhao, LJ Gao, XF Gao, DP Wang, JM Cao Frontiers in cellular and infection microbiology 10, 587269	2020
The SARS-CoV-2 main protease as drug target S Ullrich, C Nitsche Bioorganic & medicinal chemistry letters 30 (17), 127377	2020
Structural basis of potential inhibitors targeting SARS-CoV-2 main protease HM Mengist, T Dilnessa, T Jin Frontiers in Chemistry 9, 622898	2021
Structural biology of SARS-CoV-2 and implications for therapeutic development H Yang, Z Rao Nature Reviews Microbiology 19 (11), 685-700	2021
Structural characterization of SARS-CoV-2: where we are, and where we need to be G Mariano, RJ Farthing, SLM Lale-Farjat, JRC Bergeron Frontiers in molecular biosciences, 344	2020
Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2 MM Ghahremanpour, J Tirado-Rives, M Deshmukh, JA Ippolito, ... ACS medicinal chemistry letters 11 (12), 2526-2533	2020
Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors C Ma, Y Hu, JA Townsend, PI Lagarias, MT Marty, A Kolocouris, J Wang ACS pharmacology & translational science 3 (6), 1265-1277	2020
Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations CH Zhang, EA Stone, M Deshmukh, JA Ippolito, MM Ghahremanpour, ... ACS central science 7 (3), 467-475	2021
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery Z Fu, B Huang, J Tang, S Liu, M Liu, Y Ye, Z Liu, Y Xiong, W Zhu, D Cao, ... Nature communications 12 (1), 488	2021
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19 R Poduri, G Joshi, G Jagadeesh Cellular signalling 74, 109721	2020
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site J Lee, LJ Worrall, M Vuckovic, FI Rosell, F Gentile, AT Ton, NA Caveney, ... Nature communications 11 (1), 5877	2020
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives K Amporndanai, X Meng, W Shang, Z Jin, M Rogers, Y Zhao, Z Rao, ... Nature communications 12 (1), 3061	2021
Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals DW Kneller, S Galanie, G Phillips, HM O'Neill, L Coates, A Kovalevsky Structure 28 (12), 1313-1320. e3	2020
Structural biology of SARS-CoV-2: open the door for novel therapies W Yan, Y Zheng, X Zeng, B He, W Cheng Signal transduction and targeted therapy 7 (1), 26	2022
Unraveling the SARS-CoV-2 main protease mechanism using multiscale methods CA Ramos-Guzmán, JJ Ruiz-Pernía, I Tuñón ACS catalysis 10 (21), 12544-12554	2020
Progress in developing inhibitors of SARS-CoV-2 3C-like protease Q Li, CB Kang Microorganisms 8 (8), 1250	2020
Unusual zwitterionic catalytic site of SARS–CoV-2 main protease revealed by neutron crystallography DW Kneller, G Phillips, KL Weiss, S Pant, Q Zhang, HM O'Neill, L Coates, ... Journal of Biological Chemistry 295 (50), 17365-17373	2020
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19 M de Vries, AS Mohamed, RA Prescott, AM Valero-Jimenez, L Desvignes, ... Journal of Virology 95 (10), 10.1128/jvi. 01819-20	2021
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay A Narayanan, M Narwal, SA Majowicz, C Varricchio, SA Toner, ... Communications Biology 5 (1), 169	2022
Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19 W Cui, K Yang, H Yang Frontiers in molecular biosciences 7, 616341	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。